potential COVID-19 treatments - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.91 [0.86, 0.95]< 127%84 studies (84/-)100.0 %some concerncritical moderatecrucial-
death or transfer to ICU 0.84 [0.62, 1.13]< 153%5 studies (5/-)87.2 %some concernserious moderatecrucial-
deaths 0.91 [0.88, 0.95]< 118%161 studies (161/-)100.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.87 [0.80, 0.95]< 146%32 studies (32/-)99.9 %some concerncritical moderatecrucial-
clinical deterioration 0.78 [0.66, 0.91]< 148%34 studies (34/-)99.9 %some concernlow moderateimportant-
clinical improvement 1.16 [1.08, 1.25]> 148%48 studies (48/-)100.0 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.15 [1.00, 1.31]> 147%26 studies (26/-)97.6 %some concern